Advances in foamy virus vector technology and disease correction could speed the path to clinical application.
INSERM U758, Human Virology Laboratory, EVIR, Lyon, France. els.verhoeyen@ens-lyon.fr
Els
E
Verhoeyen
D000818:Animals; D002462:Cell Membrane / Q000737:chemistry*; D005260:Female; D005822:Genetic Vectors / Q000008:administration & dosage*; D006497:Heparan Sulfate / Q000378:metabolism*; D006801:Humans; D008297:Male; D011991:Receptors, Virus / Q000378:metabolism*; D016092:Spumavirus / Q000235:genetics* / Q000378:metabolism*; D014923:Wiskott-Aldrich Syndrome / Q000235:genetics* / Q000628:therapy*
D006497:Heparan Sulfate; D011991:Receptors, Virus